References
- Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001;61:2289–307
- Le Loet X, Pavelka K, Richarz U. Transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee or hip, an open, multicentre study. BMC Musculoskelet Disord 2005;6:31
- Pavelka K, Le Loet X, Bjorneboe O, Herrero-Beaumont G, Richarz U. Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control. Curr Med Res Opin 2004;20:1967–77
- Milligan K, Lanteri-Minet M, Borchert K, et al. Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J Pain 2001;2(4):197–204
- Muriel C, Failde I, Mico JA, Neira M, Sanchez-Magro I. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Clin Ther 2005;27:451–62
- Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2004;26:1808–20
- Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2003;25:150–68
- Clark AJ, Ahmedzai SH, Allan LG, et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 2004;20:1419–28
- van Seventer R, Smit JM, Schipper RM, Wicks MA, Zuurmond WW. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 2003;19:457–69
- Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Br Med J 2001;322:1154–8
- Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life [The TTS-Fentanyl Comparative Trial Group]. J Pain Symptom Manage 1997;13:254–61
- Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996;64(3):527–34
- Sathyan G, Guo C, Sivakumar K, Gidwani S, Gupta S. Bioequivalence of two transdermal fentanyl systems following single and repeat applications. Curr Med Res Opin 2005;21(12):1961–8
- Summary of products characteristics. Durogesic®. Available at: http://www.janssen-cilag.ie/product/professionals.asp
- Guidance for industry: skin irritation and sensitization testing of generic transdermal drug product. US Department of Health and Human Services; Food and Drug Administration, Centre for Drug Evaluation and Research (CDER); December 1999
- Clarys P, Alewaeters K, Lambrecht R, Barel AO. Skin color measurements: comparison between three instruments: the Chromameter®, the DermaSpectrometer® and the Mexameter®. Skin Res Technol 2000;6:230–8
- Summary of products characteristics. Transtec®. Available at: http://emc.medicines.org.uk [last updated: 13 July 2005]
- Callejo Melgosa AM, Martinez JC, Fuentes MJ, Martin C. Allergic contact dermatitis from buprenorphine. Allergy 2005;60:1217–8
- Elliott JC, Picker MJ, Nelson CJ, Carrigan KA, Lysle DT. Sex differences in opioid-induced enhancement of contact hyper-sensitivity. J Invest Dermatol 2003;121:1053–9